BRPI0509506A - forma cristalina de pirazóis, processo para a conversão da mesma, compisição farmacêutica, uso, processo para tornar a forma cristalina e processo para a produção da referida forma - Google Patents

forma cristalina de pirazóis, processo para a conversão da mesma, compisição farmacêutica, uso, processo para tornar a forma cristalina e processo para a produção da referida forma

Info

Publication number
BRPI0509506A
BRPI0509506A BRPI0509506-9A BRPI0509506A BRPI0509506A BR PI0509506 A BRPI0509506 A BR PI0509506A BR PI0509506 A BRPI0509506 A BR PI0509506A BR PI0509506 A BRPI0509506 A BR PI0509506A
Authority
BR
Brazil
Prior art keywords
crystalline form
converting
pharmaceutical composition
pyrazoles
rendering
Prior art date
Application number
BRPI0509506-9A
Other languages
English (en)
Inventor
Changquan Calvin Sun
Garry O'connor
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of BRPI0509506A publication Critical patent/BRPI0509506A/pt
Publication of BRPI0509506A8 publication Critical patent/BRPI0509506A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W16/00—Network planning, e.g. coverage or traffic planning tools; Network deployment, e.g. resource partitioning or cells structures
    • H04W16/18—Network planning tools
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W24/00—Supervisory, monitoring or testing arrangements
    • H04W24/02—Arrangements for optimising operational condition

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

FORMA CRISTALINA DE PIRAZóIS, PROCESSO PARA A CONVERSãO DA MESMA, COMPOSIçãO FARMACêUTICA, USO, PROCESSO PARA TORNAR A FORMA CRISTALINA E PROCESSO PARA A PRODUçãO DA REFERIDA FORMA. A presente invenção refere-se a formas de cristal de 4-¢5-(4- fluorofenil)-3-(trifluorometií)-1 H-pirazol-1 -il!-benzenossulfonamida e métodos para a preparação, interconversão e isolamento de tais cristais.
BRPI0509506A 2004-04-01 2005-03-21 Forma cristalina de pirazóis, processo para a conversão da mesma, composição farmacêutica, uso, processo para tornar a forma cristalina e processo para a produção da referida forma BRPI0509506A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55846904P 2004-04-01 2004-04-01
PCT/IB2005/000735 WO2005095349A1 (en) 2004-04-01 2005-03-21 Crystalline pyrazole derivative

Publications (2)

Publication Number Publication Date
BRPI0509506A true BRPI0509506A (pt) 2007-09-18
BRPI0509506A8 BRPI0509506A8 (pt) 2017-01-24

Family

ID=34961629

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509506A BRPI0509506A8 (pt) 2004-04-01 2005-03-21 Forma cristalina de pirazóis, processo para a conversão da mesma, composição farmacêutica, uso, processo para tornar a forma cristalina e processo para a produção da referida forma

Country Status (25)

Country Link
US (2) US7652149B2 (pt)
EP (1) EP1742922B1 (pt)
JP (1) JP4177883B2 (pt)
KR (1) KR100820511B1 (pt)
CN (1) CN1938276B (pt)
AR (1) AR048449A1 (pt)
AU (1) AU2005227745C1 (pt)
BR (1) BRPI0509506A8 (pt)
CA (1) CA2562104C (pt)
DK (1) DK1742922T3 (pt)
EA (1) EA008697B1 (pt)
ES (1) ES2565409T3 (pt)
HK (1) HK1099755A1 (pt)
HU (1) HUE028811T2 (pt)
IL (1) IL177711A0 (pt)
MA (1) MA28494B1 (pt)
NO (1) NO20064986L (pt)
NZ (1) NZ550907A (pt)
PL (1) PL1742922T3 (pt)
SI (1) SI1742922T1 (pt)
TN (1) TNSN06313A1 (pt)
TW (1) TW200536816A (pt)
UA (1) UA84455C2 (pt)
WO (1) WO2005095349A1 (pt)
ZA (1) ZA200607154B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA84455C2 (en) * 2004-04-01 2008-10-27 Фармациа Энд Апджон Компани Ллси Crystalline pyrazole derivatives
CA2630849C (en) 2005-12-14 2013-05-14 Makhteshim Chemical Works Ltd. Polymorphs and amorphous forms of 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1h-pyrazole-3-carbonitrile
CN101562980B (zh) 2006-11-10 2014-04-16 巴斯夫欧洲公司 锐劲特的晶型
EP2083628A1 (en) 2006-11-10 2009-08-05 Basf Se Crystalline modification of fipronil
UA110598C2 (uk) 2006-11-10 2016-01-25 Басф Се Спосіб одержання кристалічної модифікації фіпронілу
JP2017081860A (ja) * 2015-10-29 2017-05-18 株式会社トクヤマ セレコキシブの製造方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3282731B2 (ja) 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
US6492411B1 (en) 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
AU716582B2 (en) 1995-10-17 2000-03-02 G.D. Searle & Co. Method of detecting cyclooxygenase-2
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US6221153B1 (en) 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
TR200001872A3 (tr) * 2000-06-26 2002-01-21 Fako Ilaclari A.S 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine iliskin yöntem.
UA84455C2 (en) * 2004-04-01 2008-10-27 Фармациа Энд Апджон Компани Ллси Crystalline pyrazole derivatives

Also Published As

Publication number Publication date
IL177711A0 (en) 2006-12-31
CN1938276B (zh) 2011-08-10
AU2005227745B2 (en) 2008-05-29
JP4177883B2 (ja) 2008-11-05
CA2562104C (en) 2010-08-17
MA28494B1 (fr) 2007-03-01
PL1742922T3 (pl) 2016-06-30
WO2005095349A1 (en) 2005-10-13
UA84455C2 (en) 2008-10-27
KR20060131949A (ko) 2006-12-20
TW200536816A (en) 2005-11-16
AU2005227745C1 (en) 2009-02-26
AR048449A1 (es) 2006-04-26
CA2562104A1 (en) 2005-10-13
NO20064986L (no) 2006-12-21
KR100820511B1 (ko) 2008-04-11
ES2565409T3 (es) 2016-04-04
AU2005227745A1 (en) 2005-10-13
HUE028811T2 (en) 2017-01-30
NZ550907A (en) 2010-10-29
US20100093820A1 (en) 2010-04-15
TNSN06313A1 (fr) 2007-12-03
US20050222240A1 (en) 2005-10-06
US7652149B2 (en) 2010-01-26
DK1742922T3 (en) 2016-04-11
ZA200607154B (en) 2008-03-26
BRPI0509506A8 (pt) 2017-01-24
EP1742922B1 (en) 2016-02-03
EA200601601A1 (ru) 2007-02-27
JP2007530655A (ja) 2007-11-01
EA008697B1 (ru) 2007-06-29
SI1742922T1 (sl) 2016-07-29
HK1099755A1 (en) 2007-08-24
CN1938276A (zh) 2007-03-28
EP1742922A1 (en) 2007-01-17

Similar Documents

Publication Publication Date Title
BRPI0509506A (pt) forma cristalina de pirazóis, processo para a conversão da mesma, compisição farmacêutica, uso, processo para tornar a forma cristalina e processo para a produção da referida forma
CL2007003487A1 (es) Forma cristalina del hemihidrato de 1-(b-d-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno, inhibidor del transportador de glucosa sodio-dependiente; proceso de preparacion; composicion farmaceutica, util para el tratamiento de dia
UY30082A1 (es) Forma cristalina de 1-(1-metiletil)-4`-((2-fluoro-4-metoxifenil)metil)-5`- metil-1h-pirazol-3`-o-b-d-glucopiranosido, un metodo para su preparacion y el uso de la misma para preparar medicamentos
NO20073875L (no) Krystallformer av 1-klor-4-(B-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloksy)-benzyl]-benzen, metode for fremstilling samt anvendelse for fremstilling av medikamenter
EA200702586A1 (ru) Кристаллические модификации пираклостробина
NO20080243L (no) Substituerte arylpyrazoler til anvendelse mot parasitter
CR9505A (es) Formas cristalinas anhidras de la n-(1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridin-2-il-amino)-1h-pirazolo(4,3-d)pirimidina-3-cabonil)metanosulfonamida
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
UY30320A1 (es) Formas polimorficas de 1-((4-metil-quinazolin-2-il)metil)--3-metil-7-(2-butin-1-il)-8-(3-(r)-amino-piperidin-1-il)-xantina, preparaciones, composiciones de preparacion y aplicaciones de las mismas.
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
ECSP066517A (es) Nuevas formas cristalinas de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
AR068187A1 (es) Forma cristalina de un intermediario sintetico para la preparacion de un inhibidor de dpp-iv
EA200900633A1 (ru) Новая кристаллическая модификация
BRPI0912388A2 (pt) composto, forma cristalina, processo para preparar compostos, composição farmacêutica, e, uso de um composto, e, método para o tratamento ou profilaxia de doenças
EA200900641A1 (ru) Новая кристаллическая модификация
UY27410A1 (es) Formas novedosas crudas cristalinas
BRPI0711924A8 (pt) processo para a preparação de cefadroxil em forma de cristal, cefadroxil em forma de cristal e composição farmacêutica
DE602006010397D1 (de) Substituierte cyclohexanone
NO20073440L (no) Prosess for fremstilling av candesartan
BRPI0513571A (pt) processo melhorado para a fabricação de mirtazapina
CO6390054A2 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina
WO2009063504A3 (en) Novel crystal modification of epinastine or salts thereof and process for preparation thereof
BRPI0909353A2 (pt) forma de cristal, processo selecionado de preparar uma forma de cristal e preparar composto, composição farmacêutica, e, uso de uma forma de cristal
AR063491A1 (es) Modificaciones de cristal

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: PAH PANDU LLC (US)

B25D Requested change of name of applicant approved

Owner name: ZOETIS PANDU LLC (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ZOETIS SERVICES LLC (US)

B25G Requested change of headquarter approved

Owner name: ZOETIS SERVICES LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]